Coeptis now has exclusive rights to SNAP-CAR
NK and SNAP-CAR T-Cell technology platforms
WEXFORD,
Pa., Oct. 11, 2023 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the
Company"), a biopharmaceutical company developing innovative cell
therapy platforms for cancer, today announced that it has expanded
its exclusive license agreement with the University of Pittsburgh to include the SNAP-CAR
technology platform in natural killer (NK) cells. This amended
agreement builds upon the original exclusive license agreement with
the University of Pittsburgh for
SNAP-CAR T-Cell, a "universal" CAR T technology platform designed
to target multiple antigens simultaneously and potentially address
a range of hematologic and solid tumors, including HER2-expressing
cancer.
The addition of SNAP-CAR NK adds a third NK-focused technology
to Coeptis' development portfolio. Recently Coeptis completed an
exclusive license agreement with Deverra Therapeutics, which
included rights to a proprietary allogeneic stem cell expansion and
differentiation platform for the generation of NK cells from pooled
donor cord blood CD34+ cells that are being used without HLA
matching in first-in-human clinical trials. This highly scalable
and cost-effective cell generation platform combined with the
universal SNAP-CAR technology has the potential to generate a
first-in-class fully universal (no HLA matching and antigen
agnostic) targeted cell therapy. Coeptis has also obtained
exclusive rights from VyGen Bio to negotiate towards the
acquisition of the GEAR™ cell therapy and companion diagnostic
platforms, including CD38-GEAR-NK, a natural killer (NK) cell
therapy for the treatment of CD38+ cancers with an initial focus on
multiple myeloma.
"The original exclusive license agreement with the University of Pittsburgh was a watershed moment for
Coeptis, and with the growing recognition of the potential of NK
cells, we believe this amendment is another extremely important
step for this partnership and for Coeptis," said Dave Mehalick, President and CEO of Coeptis
Therapeutics. "Expanding this agreement to include engineering of
NK cells to generate SNAP-CAR NK therapies highlights our
commitment to being on the leading edge of this important
technology with a team that is fully capable of expanding upon the
existing technology to incorporate and synergize with complementary
technologies that we have brought inhouse to Coeptis, including
assets recently in-licensed from Deverra Therapeutics."
"We are pleased to expand our partnership with Coeptis as we
work to advance our efforts in developing a universal CAR-T system
and believe NK cells have the potential to be an important cell
type for developing better treatments for a range of cancers," said
Jason Lohmueller, Ph.D., Assistant
Professor of Surgery and Immunology in the Division of Surgical
Oncology Research, University of
Pittsburgh. "Expanding this agreement to include allogeneic
NK cells enables our teams to develop cell therapies that can be
developed with off-the-shelf convenience and greater access to
patients. We continue to strive for therapies that can target
multiple antigens simultaneously while also offering greater
control over toxicity."
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its
subsidiaries including Coeptis Therapeutics,
Inc. and Coeptis Pharmaceuticals,
Inc., (collectively "Coeptis"), is a biopharmaceutical
company developing innovative cell therapy platforms for cancer
that have the potential to disrupt conventional treatment paradigms
and improve patient outcomes. Coeptis' product portfolio and rights
are highlighted by assets licensed from Deverra Therapeutics,
including an allogeneic cellular immunotherapy platform and DVX201,
a clinical-stage, unmodified natural killer cell therapy
technology. Additionally, Coeptis is developing a universal,
multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the
GEAR™ cell therapy and companion diagnostic
platforms, which Coeptis is developing with VyGen-Bio and
leading medical researchers at the Karolinska Institutet.
Coeptis' business model is designed around maximizing the value of
its current product portfolio and rights through in-license
agreements, out-license agreements and co-development
relationships, as well as entering into strategic partnerships to
expand its product rights and offerings, specifically those
targeting cancer. The Company is headquartered in Wexford, PA.
For more information on Coeptis
visit https://coeptistx.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in
connection therewith contain or may contain "forward-looking
statements" (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended). Forward-looking statements include statements
concerning our plans, objectives, goals, strategies, future events
or performance, and underlying assumptions, and other statements
that are other than statements of historical facts. When we use
words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar
expressions that do not relate solely to historical matters, we are
making forward-looking statements. Forward-looking statements are
not a guarantee of future performance and involve significant risks
and uncertainties that may cause the actual results to differ
materially and perhaps substantially from our expectations
discussed in the forward-looking statements. Factors that may cause
such differences include but are not limited to: (1) the inability
to maintain the listing of the Company's securities on the Nasdaq
Capital Market; (2) the risk that the integration of the Deverra
licensed assets will disrupt current plans and operations of the
Company; (3) the inability to recognize the anticipated benefits of
the newly-licensed assets, which may be affected by, among other
things, competition, the ability of the Company to grow and manage
growth economically and hire and retain key employees; (4) the
risks that the Company's products in development or the
newly-licensed assets fail clinical trials or are not approved by
the U.S. Food and Drug Administration or other applicable
regulatory authorities; (5) costs related to integrating the
newly-licensed Deverra assets and pursuing the contemplated asset
development paths; (6) changes in applicable laws or regulations;
(7) the possibility that the Company may be adversely affected by
other economic, business, and/or competitive factors; and (8) the
impact of the global COVID-19 pandemic on any of the foregoing
risks and other risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission (the "SEC").
The foregoing list of factors is not exclusive. All forward-looking
statements are subject to significant uncertainties and risks
including, but not limited, to those risks contained or to be
contained in reports and other filings filed by the Company with
the SEC. For these reasons, among others, investors are cautioned
not to place undue reliance upon any forward-looking statements in
this press release. Additional factors are discussed in the
Company's filings made or to be made with the SEC, which are
available for review at www.sec.gov. We undertake no obligation to
publicly revise these forward-looking statements to reflect events
or circumstances that arise after the date hereof unless required
by applicable laws, regulations, or rules.
CONTACTS
Coeptis Therapeutics, Inc.
Andy Galy, Sr. VP of Communications
504-416-6965
andy.galy@coeptistx.com
Tiberend Strategic Advisors, Inc.
Investors
Daniel
Kontoh-Boateng
862-213-1398
dboateng@tiberend.com
Media
David
Schemelia
609-468-9325
dschemelia@tiberend.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-expands-license-agreement-with-university-of-pittsburgh-to-include-snap-car-nk-cell-technology-301953144.html
SOURCE Coeptis Therapeutics